Stock Yearly Return 2019
Start date: 12/31/2018
End date: 12/31/2019
Start price/share: $42.42
End price/share: $128.86
Dividends collected/share: $0.00
Total return: 203.77%
Average Annual Total Return: 203.77%
Starting investment: $10,000.00
Ending investment: $30,377.00
Years: 1.00


MRTX average annual return is presented with the assumption of reinvestments of any dividends on ex-date.
Compare MRTX average annual return versus benchmarks:

S&P Average Annual Return
Dow Average Annual Return
Nasdaq 100 Average Annual Return
Russell 2000 Average Annual Return
Gold Average Annual Return
10 Year Treasury Average Annual Return
Growth of $10,000.00
Without Dividends Reinvested Into MRTX


Also see:
MRTX stock yearly return 2020
MRTX YTD return
MRTX average annual return 10 years
Mirati Therapeutics is a clinical-stage oncology company developing product candidates to address the genetic and immunological promoters of cancer. Co.'s KRAS inhibitor program is focused on developing inhibitors of KRAS mutations and includes one clinical candidate and a preclinical program. Co. also has additional preclinical programs which include product candidates designed to address mutations and tumors where few treatment options exist. Co.'s clinical and preclinical programs consist of two product candidates: sitravatinib, a multi-kinase inhibitor and MRTX849, a KRAS G12C inhibitor. Co. has several discovery programs, including a preclinical program for a KRAS G12D inhibitor. The MRTX stock yearly return is shown above.

The yearly return on the MRTX stock yearly return page and across the coverage universe of our site, is a measure of the annual return over the calendar year 2019 for the given stock. When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is more than just the change in price if that instrument pays a dividend or coupon.

One way to factor dividends into the return is simply to count them as cash — we don't do that here. Instead, our website aims to empower investors by performing the MRTX annual return calculation with any dividends reinvested as applicable (on ex-dates).
Quotes delayed 20 minutes
Get Free SEC filing alerts for MRTX:
MRTX SEC Filing Email Alerts ServiceExternal link
10 Most Oversold Stocks in the S&P
10 Most Overbought Stocks in the S&P
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: Don't Forget Dividends in Average Annual Return!


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Mirati Therapeutics (MRTX) is categorized under the Healthcare sector; to help you further research average annual return performance across stocks, below are some other companies in the same sector:

MSON Average Annual Return
MTEM Average Annual Return
MYGN Average Annual Return
MYL Average Annual Return
MYND Average Annual Return
MYOK Average Annual Return
NAOV Average Annual Return
NBIX Average Annual Return
NDRA Average Annual Return
NEO Average Annual Return
More Healthcare companies »

 

MRTX Stock Yearly Return 2019 | www.AverageAnnualReturn.com | Copyright © 2021 - 2021, All Rights Reserved

Nothing in AverageAnnualReturn.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.